Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a fusion protein biologic that is in Phase I clinical trials designed to target and activate antigen-specific T cells for human papilloma virus driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 would also leverage the IL-2 based CUE-100 framework and target an antigen to be selected in collaboration with LG Chem; CUE-200 framework that utilizes CD80 and/or 4-1BBL to reactivate exhausted T cells and design to enhance antigen-specific T cell for the treatment of chronic infectious diseases; and CUE-300 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences to the development of Immuno-STATs focused in the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
IPO Year: 2018
Exchange: NASDAQ
Website: cuebiopharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/13/2024 | $6.00 | Buy | Jefferies |
| 6/26/2023 | $10.00 | Outperform | Oppenheimer |
| 11/21/2022 | $7.00 | Overweight | Piper Sandler |
| 1/13/2022 | $20.00 | Buy | H.C. Wainwright |
| 1/3/2022 | $28.00 | Buy | Craig Hallum |
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Cue Biopharma, Inc. (0001645460) (Issuer)
4 - Cue Biopharma, Inc. (0001645460) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Jefferies initiated coverage of Cue Biopharma with a rating of Buy and set a new price target of $6.00
Oppenheimer resumed coverage of Cue Biopharma with a rating of Outperform and set a new price target of $10.00
Piper Sandler initiated coverage of Cue Biopharma with a rating of Overweight and set a new price target of $7.00
H.C. Wainwright initiated coverage of Cue Biopharma with a rating of Buy and set a new price target of $20.00
Craig Hallum initiated coverage of Cue Biopharma with a rating of Buy and set a new price target of $28.00
Fastest customizable press release news feed in the world
Daniel Camardo, former CEO and executive commercial leader with a track record of successful launches joins the board Viola Meehan, former CFO with broad experience in governance, strategic finance and executive leadership joins the board BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a precision immuno-engineering company focused on developing transformative therapies targeting functional cures for immunological disorders, today announced the transition of its board as the Company continues its strategic growth and transformation to support late clinical stage capabilities and activities. Effective May 29, 2026, four independent directors, Jill Broadfoot, P
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage therapeutics company focused on developing transformative therapies targeting functional cures for immunological disorders, today announced that Shao-Lee Lin, president and chief executive officer, will present at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 3:10 p.m. EDT in New York City. A live audio webcast and replay of the presentation will be available through Cue Biopharma's Investor Relations website. The webcast will be archived for 90 days. About Cue BiopharmaCue Biopharma (NASDAQ:CUE) is a clinical stage therapeutics company focused on advancing a portfolio o
Enhanced the company's portfolio with an exclusive license for, CUE-221, a Phase 2 program targeting allergic disease Hosted virtual R&D day showcasing CUE-401, a bifunctional IL-2 and TGF-B program targeting autoimmune diseaseStrengthened the company's balance sheet and ability to fund anticipated cash needs with a $30 million private placement and received a $7.5 million milestone payment under a collaboration and license agreement Appointed Shao-Lee Lin, M.D., Ph.D., as President, CEO and Board Director to lead continued growth and transformation into a clinical-stage company. BOSTON, May 14, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical stage therapeuti
BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), today announced that, on May 3, 2026, the Company granted inducement equity awards to seven new employees, including its newly appointed president and chief executive officer, Shao-Lee Lin, M.D., Ph.D. The equity awards were made pursuant to the Company's 2026 Inducement Stock Incentive Plan and were unanimously approved by the independent directors of the Company as an inducement material to each new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement grants made to Dr. Lin consisted of (i) a non-statutory stock option to purchase 655,074 shares of c
BOSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, announced today that it has entered into a securities purchase agreement with certain accredited investors for a private placement (the "PIPE financing") for gross proceeds of approximately $30 million to Cue Biopharma, before placement agent fees and offering expenses. The PIPE financing is expected to close on or about May 4, 2026, subject to the satisfaction of customary closing conditions. Newbridge S
Novel dual-mechanism anti-IgE antibody designed to improve upon existing and emerging therapies for IgE-mediated diseases Cue Biopharma plans to initiate global Phase 2b trial in food allergy following anticipated results in 2H 2026 from Ascendant Health-led Phase 2 study in chronic spontaneous urticaria Transaction establishes Cue Biopharma as a clinical-stage company with a robust portfolio of therapies targeting functional cures for immunological disorders BOSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells
BOSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, today announced the appointment of Shao-Lee Lin, M.D., Ph.D., as Chief Executive Officer, President and Director. Dr. Lin will succeed Lucinda Warren, Interim President and Chief Executive Officer. "Shao-Lee's exceptional track record progressing breakthrough therapies from concept to clinic, combined with her disciplined approach to leading companies through growth, will be a massive step as we advance C
BOSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, today announced that it will implement a 1-for-30 reverse stock split of the issued shares of the company's common stock, effective at 5:00 p.m. Eastern Time on April 23, 2026. The reverse stock split was approved by the company's stockholders at the company's 2026 Annual Meeting of Stockholders held on April 13, 2026 (the "Annual Meeting"), with the final ratio subsequently determined by the company's Bo
BOSTON, April 15, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, today announced that it will present new preclinical data for its lead autoimmune and inflammatory disease candidate, CUE-401, as part of a poster at IMMUNOLOGY2026, the annual meeting of the American Association of Immunologists (AAI) taking place in Boston, Massachusetts, April 15-19, 2026. Poster Presentation Details: Title: CUE-401: A Novel Bifunctional TGF-beta/IL-2 Fusion Protein that Induces Selec
Preclinical milestone for selection and approval of first compound for lead optimization has been achievedFurther development validates the potential intended mechanistic effect of CUE-501 for T cell-mediated targeted depletion of specific B cells to address autoimmune and inflammatory diseases BOSTON, April 08, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage memory T cell subsets to deplete pathogenic B cells for the potential treatment of autoimmune and inflammatory diseases, today announced that it will receive a $7.5 million preclinical milestone payment under
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Cue Biopharma, Inc. (0001645460) (Issuer)
4 - Cue Biopharma, Inc. (0001645460) (Issuer)
3 - Cue Biopharma, Inc. (0001645460) (Issuer)
3 - Cue Biopharma, Inc. (0001645460) (Issuer)
4 - Cue Biopharma, Inc. (0001645460) (Issuer)
4 - Cue Biopharma, Inc. (0001645460) (Issuer)
4 - Cue Biopharma, Inc. (0001645460) (Issuer)
4 - Cue Biopharma, Inc. (0001645460) (Issuer)
4 - Cue Biopharma, Inc. (0001645460) (Issuer)
4 - Cue Biopharma, Inc. (0001645460) (Issuer)
8-K - Cue Biopharma, Inc. (0001645460) (Filer)
S-8 - Cue Biopharma, Inc. (0001645460) (Filer)
S-3 - Cue Biopharma, Inc. (0001645460) (Filer)
8-K - Cue Biopharma, Inc. (0001645460) (Filer)
DEF 14A - Cue Biopharma, Inc. (0001645460) (Filer)
8-K - Cue Biopharma, Inc. (0001645460) (Filer)
10-Q - Cue Biopharma, Inc. (0001645460) (Filer)
D - Cue Biopharma, Inc. (0001645460) (Filer)
PRE 14A - Cue Biopharma, Inc. (0001645460) (Filer)
8-K - Cue Biopharma, Inc. (0001645460) (Filer)
This live feed shows all institutional transactions in real time.
SC 13G - Cue Biopharma, Inc. (0001645460) (Subject)
SC 13G - Cue Biopharma, Inc. (0001645460) (Subject)
SC 13G - Cue Biopharma, Inc. (0001645460) (Subject)
SC 13G - Cue Biopharma, Inc. (0001645460) (Subject)
SC 13G/A - Cue Biopharma, Inc. (0001645460) (Subject)
SC 13G/A - Cue Biopharma, Inc. (0001645460) (Subject)
SC 13G - Cue Biopharma, Inc. (0001645460) (Subject)
SC 13G - Cue Biopharma, Inc. (0001645460) (Subject)
SC 13G/A - Cue Biopharma, Inc. (0001645460) (Subject)
SC 13G/A - Cue Biopharma, Inc. (0001645460) (Subject)
Live Leadership Updates
Daniel Camardo, former CEO and executive commercial leader with a track record of successful launches joins the board Viola Meehan, former CFO with broad experience in governance, strategic finance and executive leadership joins the board BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a precision immuno-engineering company focused on developing transformative therapies targeting functional cures for immunological disorders, today announced the transition of its board as the Company continues its strategic growth and transformation to support late clinical stage capabilities and activities. Effective May 29, 2026, four independent directors, Jill Broadfoot, P
Novel dual-mechanism anti-IgE antibody designed to improve upon existing and emerging therapies for IgE-mediated diseases Cue Biopharma plans to initiate global Phase 2b trial in food allergy following anticipated results in 2H 2026 from Ascendant Health-led Phase 2 study in chronic spontaneous urticaria Transaction establishes Cue Biopharma as a clinical-stage company with a robust portfolio of therapies targeting functional cures for immunological disorders BOSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells
BOSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, today announced the appointment of Shao-Lee Lin, M.D., Ph.D., as Chief Executive Officer, President and Director. Dr. Lin will succeed Lucinda Warren, Interim President and Chief Executive Officer. "Shao-Lee's exceptional track record progressing breakthrough therapies from concept to clinic, combined with her disciplined approach to leading companies through growth, will be a massive step as we advance C
BOSTON, March 27, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, today announced that Lucinda Warren, an industry veteran who has served as Cue Biopharma's chief financial and business officer since February 2026 and previously as Cue Biopharma's chief business officer from September 2024 until February 2026, has been appointed interim president and chief executive officer (CEO). Usman Azam has stepped down as president and CEO and as a director, effective March 26, 202
BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, today announced that Lucinda Warren, who has served as Cue Biopharma's chief business officer (CBO) since September 2024, has been appointed chief financial and business officer (CFBO) effective February 9, 2026. "The combination of Lucinda's financial and business acumen together with her extensive background makes the CFBO a key strategic partner in helping drive business growth and Company success, part
BOSTON, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced the appointment of industry veteran Lucinda Warren as chief business officer (CBO). With an extensive background and proven expertise in strategic transactions, portfolio optimization and alliance management through her extensive tenure at Johnson & Johnson and Jansen, Ms. Warren will play a pivotal role in advancing Cue Biopharma's core corporate objectives following the company's recent business restructuring and autoimmune program prioritizati
BOSTON, April 25, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body, announced today the appointment of seasoned pharmaceutical executive Pamela D. Garzone, Ph.D., to its board of directors. Dr. Garzone brings to Cue Biopharma more than 25 years of healthcare and pharmaceutical industry experience in drug development, including strategic, scientific, clinical and regulatory leadership expertise. "We are pleased to have Dr. Garzone join our board of directors," said Daniel Passeri, chief executive
BOSTON, April 12, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body, announced today the appointment of industry veteran Patrick Verheyen to its board of directors (BOD). Mr. Verheyen brings to Cue Biopharma more than 35-years of experience facilitating pipeline growth and innovation programs at Janssen Pharmaceutical Companies of Johnson and Johnson. "We are very pleased to welcome Mr. Verheyen to our BOD and leverage his extensive experience and guidance as we seek to enhance and broaden Cue Bi
BOSTON, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body, announced today that world-renowned immunologist and distinguished thought leader Dr. Rafi Ahmed, Ph.D., has joined its Scientific Advisory Board (SAB). Dr. Ahmed's research has significantly shaped the scientific community's current understanding of immunity in the context of viral infections and cancer. His extensive work on defining T cell exhaustion along with detailing molecular underpinnings of T cell differentiation and ef
Matteo Levisetti, M.D., promoted to Chief Medical Officer, effective January 17, 2023Acting CMO Kenneth Pienta, M.D., to transition to a clinical advisory role BOSTON, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body, announced today that Matteo Levisetti, M.D., senior vice president (SVP) of clinical development at Cue Biopharma, has been promoted to Chief Medical Officer (CMO) effective January 17, 2023. Current acting CMO Kenneth Pienta, M.D., has transitioned from his current role
Live finance-specific insights
BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announced that it will host a conference call and webcast to provide a business update on Tuesday, April 15, 2025 at 4:30 p.m. ET. Conference Call and Webcast DetailsTuesday, April 15 at 4:30 p.m. ET Investors:1-844-826-3035International Investors:1-412-317-5195Conference ID:10199037Webcast Link:https://viavid.webcasts.com/starthere.jsp?ei=1715808&tp_key=9378826572 The live and archived webcast will also b
BOSTON, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, announced today that it will host a conference call and webcast to provide a business update on Monday, August 19, 2024 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company's website. The company will provide a business overview of its recent restructuring and near-term strategic prioritization objectives. The discussion will focus on the company's approach to enhance near-term shareholder value by refocusing resourc
BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will host a conference call and webcast to provide a business update on Monday, April 8, 2024 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company's website. The Company will provide a corporate update highlighting measurable progress advancing its lead clinical oncology programs, CUE-101 and CUE-102, its lead preclinical autoimmune program CUE-401 partnered with Ono Pharmaceutical, as well as additional au
BOSTON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of T cell engagers to selectively modulate tumor-specific T cells, announced today that it will host a conference call and webcast to provide a business and clinical update on Thursday, November 9, 2023 at 4:30 p.m. ET. Live and archived versions of the event can be accessed via the Company's website. The Company will provide a clinical update from its Phase 1 trials evaluating the lead interleukin 2 (IL-2)-based biologic, CUE-101, as monotherapy and in combination with KEYTRUDA® (pembrolizumab) for patients with recurrent/metastatic HPV+ he
BOSTON, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body, announced today that it will host a conference call and webcast to provide a business and clinical update on Wednesday, August 9, 2023 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company's website. The company will provide a clinical update from its ongoing Phase 1 trial evaluating CUE-101, the company's lead interleukin 2 (IL-2)-based biologic from the CUE-100 series, in combination with pem
BOSTON, March 15, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body, announced today that it will host a conference call and webcast to provide a business and clinical update on Tuesday, March 21, 2023 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company's website. Members of the Cue Biopharma executive management team will provide a clinical update from the Company's ongoing trials evaluating its lead interleukin 2 (IL-2)-based biologic, CUE-101, as a monothe
BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient's body, announced today that it will host a conference call and webcast to provide a business update on Monday, November 14, 2022 at 4:30 p.m. EST. Live and archived versions of the event can be accessed via the Company's website. Members of the Cue Biopharma executive management team will provide an update and summary of the data presented at the Society for Immunotherapy of Cancer's 37th Annual Meeting (SITC 2022) highlighting the Compan
Early data in the combination study of CUE-101 and KEYTRUDA® (pembrolizumab) supports synergistic activity; of four patients treated in dose escalation in the 2mg/kg and RP2D 4mg/kg cohorts, two have partial responses (1 confirmed and 1 unconfirmed) and two are manifesting reductions in target lesions Updated CUE-101 monotherapy data further enhances confidence in potential as single agent therapeutic with 50% clinical benefit rate reported to date in RP2D (4mg/kg) expansion monotherapy trial and an emerging enhanced overall survival rate that supports the premise that CUE-101 selectively stimulates cancer-relevant CD8+ T cells CAMBRIDGE, Mass., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Cue Bioph
CAMBRIDGE, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient's body, announced today it will host a conference call and webcast to provide a clinical update on Wednesday, January 26, 2022 at 4:30 p.m. EST. Live and archived versions of the event can be accessed via the Company's website. Members of the Cue Biopharma executive management team will provide an update from the Company's ongoing clinical trials with CUE-101, its lead and representative IL-2 based drug product candidate from
CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient's body, announced today it will host a conference call and webcast to provide a business update on Tuesday, August 17, 2021 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company's website. Members of the Cue Biopharma executive management team will provide a clinical update from the Company's clinical trials with CUE-101, its lead and representative IL-2 based drug product candidate from th